Cargando…
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
BACKGROUND: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that NC-6004 could show lower toxicity than cisplatin and show greater anti-tumour activity in phase I study. METHODS: A total of 17 patients were recruited in a range of advanc...
Autores principales: | Plummer, R, Wilson, R H, Calvert, H, Boddy, A V, Griffin, M, Sludden, J, Tilby, M J, Eatock, M, Pearson, D G, Ottley, C J, Matsumura, Y, Kataoka, K, Nishiya, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049602/ https://www.ncbi.nlm.nih.gov/pubmed/21285987 http://dx.doi.org/10.1038/bjc.2011.6 |
Ejemplares similares
-
Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
por: Uchino, H, et al.
Publicado: (2005) -
NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis
por: Doi, Toshihiko, et al.
Publicado: (2017) -
Cisplatin‐incorporated Polymeric Micelles Eliminate Nephrotoxicity, While Maintaining Antitumor Activity
por: Mizumura, Yasuo, et al.
Publicado: (2001) -
Development of polymeric micelles for targeting intractable cancers
por: Nishiyama, Nobuhiro, et al.
Publicado: (2016) -
A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer
por: Volovat, Simona Ruxandra, et al.
Publicado: (2020)